Kingdon Capital Management’s Heron Therapeutics HRTX Stock Holding History

Kingdon Capital Management’s Portfolio HRTX Stock Details HRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-150,000	Closed	-$3.67M	–	75
2019 Q1	$3.67M	Buy	+150,000	New	+$3.93M	0.49%	48
2018 Q3	–	Sell	-216,600	Closed	-$8.41M	–	116
2018 Q2	$8.41M	Sell	216,600 -183,100	-46%	-$5.83M	0.59%	64
2018 Q1	$11M	Sell	399,700 -15,300	-4%	-$347K	0.87%	44
2017 Q4	$7.51M	Hold	415,000	–	–	0.48%	64
2017 Q3	$6.7M	Sell	415,000 -661,500	-61%	-$10.4M	0.44%	64
2017 Q2	$14.9M	Buy	+1,076,500	New	+$15.6M	1.02%	35
2017 Q1	–	Sell	-1,035,000	Closed	-$13.6M	–	119
2016 Q4	$13.6M	Buy	+1,035,000	New	+$16.2M	0.66%	52
2016 Q3	–	Sell	-376,700	Closed	-$6.8M	–	124
2016 Q2	$6.8M	Hold	376,700	–	–	0.37%	69
2016 Q1	$7.15M	Sell	376,700 -423,300	-53%	-$8.35M	0.39%	61
2015 Q4	$21.4M	Sell	800,000 -730,000	-48%	-$19.5M	1.04%	24
2015 Q3	$37.3M	Sell	1,530,000 -170,000	-10%	-$5.67M	1.8%	14
2015 Q2	$53M	Buy	1,700,000 +1,300,000	+325%	+$24.5M	2.07%	12
2015 Q1	$5.82M	Buy	+400,000	New	+$4.51M	0.25%	103

Other funds holding HRTX

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Kingdon Capital Management's HRTX Position: Q4 2019 in Review

Kingdon Capital Management sold out of Heron Therapeutics (HRTX) in Q4 2019, closing a stake of 505,729 shares — an estimated $9.36M sold.

Kingdon Capital Management first reported a position in HRTX in Q1 2014 and held it in 23 quarters. The position peaked at $46.5M in Q3 2016. 199 funds tracked by Wall St. Rank hold HRTX as of Q4 2019.

Kingdon Capital Management reported no remaining Heron Therapeutics position as of Q4 2019 after selling out during the quarter.
Kingdon Capital Management sold 505,729 Heron Therapeutics shares in Q4 2019, an estimated $9.36M.
Kingdon Capital Management first reported a position in Heron Therapeutics in Q1 2014 and held it in 23 quarters.
Kingdon Capital Management's Heron Therapeutics position peaked at $46.5M in Q3 2016.
199 funds tracked by Wall St. Rank held Heron Therapeutics as of Q4 2019.

Based on Kingdon Capital Management's 13F filing for Q4 2019, filed 14 Feb 2020.